Peter Nicklin is a Managing Director and Head of European Equity Advisory in Rothschild & Co’s Equity Markets Solutions team based in London. He has over 23 years of industry experience. Peter has been a specialist in Equity Capital Markets throughout his career, and holds a degree in Economics and Politics from the University of Bristol.

Peter Nicklin has more than 30 years of extensive experience and background in the pharmaceutical and healthcare sector in both developed, as well as emerging markets and significant experience in leading global teams. Chair of the Board at …

2022年5月30日 · Hansa Biopharma AB, “Hansa”, (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, today announces that Peter Nicklin has been proposed as new Chairman of the Board at Hansa Biopharma.

Mr. Peter Nicklin serves as Managing Director and Head of European Equity Advisory at Rothschild & Co. He has been a specialist in Equity Capital Markets throughout his career, and holds a degree in Economics and Politics from the University of Bristol.

Chairman at Hansa Biopharma AB, Discover Peter Nicklin's known position history, network and 100 relationships. Find out about his known public assets.

2017年6月1日 · Peter Nicklin is a senior healthcare executive with 25 years operational experience, based on a finance background. He has extensive international experience over many years with a very broad healthcare perspective including pharmaceuticals. His career is highlighted by significant business development leadership and turnaround experience. Until

2021年3月23日 · Global health and care technology company Tunstall Healthcare has announced the appointment of Peter Nicklin as Chairman of the Board in a move which it hopes will build on its position in the sector and drive forward its strategy.